FDA's OK Lets Bausch & Lomb Join Eye-Laser Price War

 

The Food and Drug Administration has approved Bausch & Lomb's (BOL) Technolas 217 Excimer Laser System, bringing another corrective eye surgery laser machine into a highly competitive market currently engaged in a price war.

Bausch & Lomb said it would immediately begin marketing Technolas 217 in the U.S., selling the laser at a list price of $525,000 per unit. The Rochester, N.Y.-based company will collect a fee of $100 per procedure from doctors using the technology.

Bausch & Lomb's announcement comes on the heels of an industrywide price war that has heated up as U.S. manufacturers of corrective laser technologies have slashed their prices.

On Thursday, the Wall Street Journal reported that Summit Technology (BEAM) said it would lower royalty fees it charges doctors for each use to $100 from $250 for some of its machines. That decision came after VISX (VISX) announced a similar price cut earlier this week.

LaserSight (LASE) intends to charge about $130 for its system, the paper said.

News of price cuts have sent laser-equipment makers' shares downward. On Wednesday, VISX fell 5 9/16 to 16 5/16, Summit dropped 4 1/4 to 7 13/16, LaserSight was off 1 25/32 to 9 23/32 and Bausch & Lomb shed 1 1/2 to close at 58 1/2. On Thursday, VISX closed up 2 3/8, or 15%, 18 3/4; Summit finished up 3/16, or 2.4%, at 8; LaserSight closed up 1/32 at 9 3/4; and Bausch & Lomb finished up 11/16, or 1.2%, 59 3/16.

>To order reprints of this article, click here: Reprints

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,769.90 1,341.50 2,906.44 19.83
Oil *
117.41
DOWN
120.56
DOWN
10.45
DOWN
20.79
DOWN
0.64
10 Yr
1.98%
SPDR Gold
167.24
-0.94%
-0.77%
-0.71%
-3.13%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet